Mold‑Tek shifts into higher‑margin packaging
An investor thread highlighted Mold‑Tek Packaging’s strategic pivot from paint cans into higher‑margin FMCG and pharma packaging as capex winds down and operating leverage kicks in, a clear case of driver‑based margin improvement highlighted. The example underlines how product mix and capex timing can flip margin trajectories in packaging supply chains.
Revenue from operations for FY2024–25 reached ₹78,132 lakh, up 11.83% year‑on‑year, while EBITDA rose to ₹14,386 lakh (a 6.98% increase), according to the company’s 2024–25 annual report. moldtekpackaging.com The pharma packaging vertical crossed into breakeven during FY25 and was singled out as a breakout performer in recent analyst coverage. alphastreet.com Broker and market notes recorded a sharp quarter‑on‑quarter expansion in pharma revenues, citing Q2 FY26 pharma sales of about ₹10.81 crore and a ~45% uplift from Q1, reflecting early commercial traction. multibagg.ai Management commentary and filings show depreciation climbed to ₹48.68 crore in FY25 from ₹38.50 crore the prior year, and management signalled a moderation in gross capex with FY26 capex guidance around ₹100–105 crore. marketsetup.in Analysts point to a step‑up in realized profitability per unit, with Ebitda/kg guidance of roughly ₹41–42 for FY26–27 tied to richer mix and IML adoption by large customers such as Asian Paints and an Aditya Birla engagement. ndtvprofit.com Quarterly market reports showed revenue of ₹210 crore and a 19% operating margin in Q2 FY26, while Q3 commentary flagged sequential margin pressure from higher finance costs even as pharma contribution rose—illustrating a clear mix vs. cost trade‑off to track. eduinvesting.in
